{
    "id": 22765,
    "fullName": "CBL del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CBL del indicates a deletion of the CBL gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 867,
        "geneSymbol": "CBL",
        "terms": [
            "CBL",
            "C-CBL",
            "CBL2",
            "FRA11B",
            "NSLL",
            "RNF55"
        ]
    },
    "variant": "del",
    "createDate": "05/18/2016",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6425,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in a mouse model of myeloproliferative disorder (PMID: 26177294).",
            "molecularProfile": {
                "id": 23386,
                "profileName": "CBL del CBLB del"
            },
            "therapy": {
                "id": 1777,
                "therapyName": "Fasudil",
                "synonyms": null
            },
            "indication": {
                "id": 4960,
                "name": "bone marrow cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5583,
                    "pubMedId": 26177294,
                    "title": "Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26177294"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23384,
            "profileName": "CBL del",
            "profileTreatmentApproaches": [
                {
                    "id": 17005,
                    "name": "FLT3 Inhibitor",
                    "profileName": "CBL del"
                }
            ]
        },
        {
            "id": 23386,
            "profileName": "CBL del CBLB del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}